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Factor for Mobilization of CD341 Hematopoietic Stem
Cells in Patients with Multiple Myeloma and Low
Peripheral Blood CD341 Cell Count: Results of a Subset
Analysis of a Randomized Trial
Auayporn P. Nademanee,1 John F. DiPersio,2 Richard T. Maziarz,3 Edward A. Stadtmauer,4
Ivana N. Micallef,5 Patrick J. Stiff,6 Frank J. Hsu,7 Gary Bridger,7 Brian J. Bolwell81Preapheresis peripheral blood (PB)CD34 cell count is a strong predictorof hematopoietic stem cell (HSC)mo-
bilization and is routinely used tooptimize the timing, cost, and success ofHSCcollection in patientswithmultiple
myeloma. However, a uniform PB CD341 cell count that predicts mobilization failure has not been defined, re-
sulting in the development of institute-specific algorithms for mobilization, particularly regarding the decision of
when to use the novel stem cell mobilization agent plerixafor. In this post hoc analysis, we evaluated the mobi-
lization efficacy of plerixafor plus granulocyte colony-stimulating factor (G-CSF) versus placebo plus G-CSF in
patients with multiple myeloma, stratified by preapheresis PB CD341 cell count:\10,\15,\20, and $20
cells/mL. Regardless of the PB CD341 cell count, the total yield of CD341 cells from apheresis was significantly
higher in the plerixafor group than in the placebo group, and significantly more patients in the plerixafor group
collected theminimum($2 106 cells/kg) andoptimum ($6 106 cells/kg) stemcell yieldsoneachdayof apher-
esis. As a corollary, the greater stem cell collection in plerixafor-treated patients resulted in the need for signif-
icantly fewer days of apheresis to reach minimum and optimum cell doses across all cell count groups. For all
CD341 cell count groups, the proportionof patients proceeding to transplantation and themedian time toplate-
let and neutrophil engraftment were similar in the plerixafor and placebo groups. Our findings demonstrate that
in patientswithmultiplemyelomawhomight be predicted to fail mobilization basedon lowPBCD341 cell count,
the addition of plerixafor to G-CSF allows for collection of the minimal and optimal cell doses in a greater pro-
portion of patients comparedwithG-CSF alone. In addition, plerixafor plusG-CSF significantly improves the like-
lihood of optimal HSC collection in patients with higher preapheresis PB CD341 cell counts ($20 cells/mL)
compared with placebo plus G-CSF. Collectively, this analysis of predicted poor mobilizers validates the superi-
ority of plerixafor plusG-CSF comparedwithG-CSF alone,which had beendemonstrated previously in theover-
all patient population.
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Preapheresis peripheral blood (PB) CD341 cell
count is a strong predictor of hematopoietic stem
cell (HSC) mobilization and collection success in
patients with multiple myeloma (MM) [1-4]. Routine
monitoring of PB CD341 cell numbers is standard
practice to optimize the timing, cost, and success of
HSC collection after mobilization [1,5]. Despite
routine use, however, a uniform cell count of
circulating CD341 cells to predict the success of
mobilization has not yet been established [1-6].
Various CD341 cell count values, ranging from 5
cells/mL to 15 cells/mL, have been used in studies to
Figure 1. Stem cell mobilization and collection schemes.
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with Low Peripheral Blood CD34+ Cell Countidentify patients at risk for mobilization failure [2,3,6],
and a PB CD341 cell count of 20 cells/mL has been
used to initiate HSC collection with a high rate of
success [4,7-9]. In one study, however, only 54% to
58% of patients who were mobilized with
granulocyte-colony stimulating factor (G-CSF) or
G-CSF plus chemotherapy had a preapheresis PB
CD341 cell count$20 cells/mL [8]. Thus, a substantial
proportion of patients remain likely to experience sub-
optimal HSC collection yields.
Plerixafor is a bicyclam molecule that blocks the
binding of stromal cell–derived factor-1a to the
CXCR4 chemokine receptor [10,11], resulting in
elevated levels of circulating HSCs in humans and
animal models [12,13]. Plerixafor, in combination
with G-CSF, is currently approved in the United
States for mobilization of HSCs for collection and
subsequent autologous stem cell transplantation
(ASCT) in patients with non-Hodgkin lymphoma or
MM [14]. The safety and efficacy of plerixafor plus
G-CSF in front-line mobilization of HSCs in patients
withMMhas been demonstrated in a phase 3, random-
ized, placebo-controlled study (Study 3102) [15]. In
that study, a significantly higher percentage of patients
treated with plerixafor plus G-CSF achieved optimal
CD341 stem cell yields for ASCT in fewer apheresis
days compared with patients treated with placebo
plus G-CSF. Transplantation outcomes for the
plerixafor-treated patients (n 5 142; 95.9%) and
placebo-treated patients (n 5 136; 88.3%) who pro-
ceeded to ASCT were similar in the 2 groups, with
99.3% of plerixafor-treated patients and 100% of
placebo-treated patients achieving neutrophil engraft-
ment. In addition, a total of 99.3% of patients in each
treatment group experienced successful platelet en-
graftment [15].
Patients with a low PB CD341 cell count (\20
cells/mL) are generally considered ‘‘poor’’ mobilizers.
The purpose of this post hoc analysis was to evaluate
the efficacy of plerixafor plus G-CSF compared with
placebo plus G-CSF in the mobilization of HSCs in
patients with MM who have low preapheresis PB
CD341 cell counts.METHODS
Study Design
This study was a post hoc analysis of data obtained
from a prospective, randomized, double-blind, pla-
cebo-controlled, phase 3 clinical trial that compared
the safety and efficacy of plerixafor (0.24 mg/kg/day
s.c.) plus G-CSF (10 mg/kg/day) and placebo plus
G-CSF for HSC mobilization and autologous HSC
transplantation (HSCT) in patients with MM [15]. In-
stitutional Review Board approval was obtained at each
site in the original study. Because no new information
was collected for the post hoc analysis, separate Institu-
tional Review Board approval was not requested.
Patients with available data on PB CD341 cell
counts on both day 4 and day 5 were included in this
analysis (Figure 1). In accordancewith clinical practice,
the patients were divided into 4 groups based on base-
line PB CD341 cell count on day 4:\10 cells/mL,\15
cells/mL,\20 cells/mL, and $20 cells/mL. Endpoints
for this post hoc analysis were the fold-increase in PB
CD341 cells; the proportion of patients achieving the
minimum ($2  106 CD341 cells/kg) and optimum
($6  106 CD341 cells/kg) cell doses at days 1, 2, 3,
and 4 of apheresis; apheresis yields; patients proceed-
ing to HSCT; and time to engraftment. Comparisons
were made between the plerixafor and placebo groups
stratified by day 4 PB CD341 cell count.Patient Eligibility
Patients enrolled in the 3102 Study were aged 18 to
78 years with biopsy-confirmed MM in first or second
complete or partial remission. Eligibility criteria were
$4 weeks since the last cycle of chemotherapy, Eastern
Cooperative Oncology Group performance status of
0 or 1,WBCcount.2.5 109 cells/L, absolute neutro-
phil count.1.5109 cells/L,platelet count.100109
cells/L, serum creatinine #2.2 mg/dL, normal liver
function, and normal cardiac and pulmonary status. Ex-
clusion criteria were previous autologous or allogeneic
HSCT, failed previous HSC collection attempt, receipt
of G-CSF within 14 days of the first dose of G-CSF on
1566 Biol Blood Marrow Transplant 18:1564-1572, 2012A. P. Nademanee et al.the study, receipt of bone-seeking radionuclides or radi-
ation therapy to$50% of the pelvis, and receipt of tha-
lidomide, lenalidomide, dexamethasone, or bortezomib
within 7 days of the first dose of G-CSF on the study.
Mobilization and Transplantation
Patients underwent mobilization withG-CSF each
morning for up to 8 days. Beginning on the evening of
day 4, patients received either plerixafor or placebo
(s.c.) daily for up to 4 days or until $6  106 CD341
cells/kg were collected. Apheresis (3.0 blood
volume 6 10%) began on day 5 and was continued
daily for up to 4 days or until $6  106 CD341
cells/kg were collected (Figure 1). HSCT using col-
lected CD341 cells (minimum 2  106 cells/kg) was
performed within 5 weeks of the last apheresis.
PB CD341 Cell Enumeration
Blood samples to measure peripheral CD341 cell
count were obtained within approximately 30 minutes
before G-CSF administration on day 4 (before plerix-
afor/placebo treatment) and on day 5 (10-11 hours af-
ter plerixafor/placebo dosing). Fluorescence-activated
cell sorter analysis was used to enumerate CD341 cells
in venous samples. The fold increase in the number of
PB CD341 cells was calculated for each treatment
group and expressed as a ratio of the pre–G-CSF
CD341 cells/mL on day-5 to pre–G-CSF CD341
cells/mL on day 4. Day 5 central laboratory values
were used exclusively for this analysis; day-4 values
were measured by local laboratories, and thus, day-4
local values were used for this analysis.
Engraftment Criteria
Neutrophil engraftmentwas defined as a neutrophil
count$0.5 109 cells/L for 3 days or$1.0 109 cells/
L for 1 day. Platelet engraftment was defined as a plate-
let count $20  109 cells/L without a transfusion for
the preceding 7 days. For patients undergoing multiple
HSCTs, engraftment was reported for the first trans-
plantation only.
Statistical Analysis
P values were calculated using Wilcoxon’s rank-
sum test. For continuous outcomes and the c2 test
for dichotomous outcomes. A P value of\.05 was con-
sidered to indicate statistical significance. All analyses
were performed using SAS version 8.2 or later (SAS
Institute, Cary, NC).RESULTS
Patients
In the 3102 Study, a total of 302 patients were ran-
domized to receive plerixafor plus G-CSF (n5 148) orplacebo plus G-CSF (n 5 154) [15]. Patients with
available PB CD341 cell count data on day 4 were in-
cluded in this post hoc analysis (plerixafor group,
n 5 129 [87.2%]; placebo group n 5 129 [83.8%]).
Patients were classified by day-4 cell count into the fol-
lowing groups:\10 cells/mL,\15 cells/mL,\20 cells/
mL, and $20 cells/mL. Patient baseline characteristics
and demographic data are summarized in Table 1.
There were no significant differences between the
plerixafor and placebo groups with respect to baseline
characteristics, regardless of cell count group.
Efficacy
PB CD341 counts
Median absolute PB CD341 cell counts on day 4
were comparable between the plerixafor-treated and
placebo-treated patients in each cell count group
(Table 2). However, the median PB CD341 cell count
on day 5 was significantly greater in the plerixafor-
treated patients across all cell count groups (\10:
48.5 versus 11.6 cells/mL; \15: 52.1 versus 18.0
cells/mL;\20: 66.0 versus 20.2 cells/mL; $20: 149.7
versus 55.5 cells/mL; P\ .001 for the plerixafor versus
placebo comparison in each cell count group)
(Table 2). The median fold increase in PB CD341
cell counts between day 4 and day 5 was significantly
in the plerixafor-treated patients across all cell count
groups (\10: 9.6-fold versus 2.0-fold; \15: 7.7-fold
versus 2.0-fold; \20: 6.6-fold versus 2.0-fold; $20:
4.1-fold versus 1.4-fold) (P\ .001) (Table 2).
CD341 stem cell collection
In nearly every comparison between the plerixafor
and placebo groups across cell count groups, a signifi-
cantly greater proportion of plerixafor-treated patients
collected the minimum ($2  106 CD341 cells/kg)
and optimum ($6  106 CD341 cells/kg) cell doses
in 1, 2, 3, and 4 days of apheresis (minimum: P 5 not
significant for plerixafor versus placebo in the $20
cells/mL group on days 2, 3, and 4; all other compari-
sons were significant; optimum: P5 not significant for
plerixafor versus placebo in the\10 cells/mL group on
day 1 and in the\10 cells/mL and\15 cells/mL groups
on day 4; all other comparisons were significant)
(Figures 2 and 3). Moreover, significantly higher me-
dian cumulative CD341 cell yields were collected in
the patients in the plerixafor group across all cell count
groups on each day of apheresis (4-day totals: \10
cells/mL: 5.83  106 cells/kg versus 3.03  106 cells/
kg [P5 .003];\15 cells/mL: 7.06 106 cells/kg versus
3.98  106 cells/kg [P \ .001]; \20 cells/mL:
8.71  106 cells/kg versus 4.67  106 cells/kg
[P\ .001]; $20 cells/mL: 14.34  106 cells/kg versus
7.43  106 cells/kg [P\ .001]) (Figure 4).
Patients in the plerixafor group collected minimum
and optimum cell doses in significantly fewer days of
Table 1. Baseline Characteristics and Patient Demographics, by Day 4 PB CD34+ Cell Count
Day 4 PB CD34+ Count, Cells/mL
<10 <15 <20 $20
Plerixafor + G-CSF
(n 5 27)
Placebo + G-CSF
(n 5 30)
Plerixafor + G-CSF
(n 5 40)
Placebo + G-CSF
(n 5 47)
Plerixafor + G-CSF
(n 5 56)
Placebo + G-CSF
(n 5 60)
Plerixafor + G-CSF
(n 5 73)
Placebo + G-CSF
(n 5 69)
Median age (range), years 57 (43-75) 64 (38-73) 59 (43-75) 62 (38-73) 57 (40-75) 62 (38-74) 58 (28-75) 57 (28-75)
Time from diagnosis to randomization,
months, median (range)
8 (5-162) 8 (4-31) 8 (3-162) 8 (2-31) 7 (3-162) 8 (2-33) 6 (3-80) 6 (3-145)
Time from most recent progression/relapse
to randomization, months, median (range)
5 (2-18) 4 (3-7) 5 (2-18) 4 (3-12) 5 (2-18) 4 (3-12) 4 (2-7) 4 (2-11)
Previous novel agent, n (%)* 23 (85.2) 24 (80.0) 30 (75.0) 39 (83.0) 44 (78.6) 48 (80.0) 51 (69.9) 46 (66.7)
Previous radiotherapy, n (%)
Yes 10 (37.0) 10 (33.3) 13 (32.5) 17 (36.2) 20 (36.4) 20 (33.3) 17 (23.3) 15 (22.1)
No 17 (63.0) 20 (66.7) 27 (67.5) 30 (63.8) 35 (63.6) 40 (66.7) 56 (76.7) 53 (77.9)
Current stage of disease, n (%) 0 0 0
I 6 (22.2) 3 (10.0) 8 (20.0) 40 (8.5) 12 (21.4) 06 (10.0) 12 (16.4) 07 (10.1)
II 5 (18.5) 6 (20.0) 7 (17.5) 11 (23.4) 9 (16.1) 17 (28.3) 11 (15.1) 19 (27.5)
III 14 (51.9) 19 (63.3) 22 (55.0) 29 (61.7) 31 (55.4) 33 (55.0) 41 (56.2) 36 (52.2)
IV 0 0 0 0 0 0 0 0
Missing 2 (7.4) 2 (6.7) 3 (7.5) 3 (6.4) 4 (7.1) 4 (6.7) 9 (12.3) 7 (10.1)
*Novel agent refers to thalidomide, bortezomib, lenalidomide, or a combination regimen including one or more of these agents.
Table 2. Median Absolute PB CD34+ Cell Count on Days 4 and 5, by Cell Count Group
PB CD34+ Count, Cells/mL, on Day 4
<10 <15 <20 $20
Plerixafor + G-CSF
(n 5 27)
Placebo + G-CSF
(n 5 30)
Plerixafor + G-CSF
(n 5 40)
Placebo + G-CSF
(n 5 47)
Plerixafor + G-CSF
(n 5 56)
Placebo + G-CSF
(n 5 60)
Plerixafor + G-CSF
(n 5 73)
Placebo + G-CSF
(n 5 69)
Absolute PB CD34+ count,
cells/mL, median (range)
Day 4 6.0 (0.4-9.5) 6.2 (2.6-9.5) 8.0 (0.4-14.4) 8.0 (2.6-14.4) 10.5 (0.4-18.0) 9.8 (2.6-19.9) 32.5 (20.0-324.5) 35.6 (20.0-243.0)
Day 5* 48.5 (4.0-314.6) 11.6 (1.2-55.8) 52.1 (4.0-314.6) 18.0 (1.2-48.0) 66.0 (4.0-314.6) 20.2 (1.2-55.8) 149.7 (0.1-1291.7) 55.5 (1.2-2002.4)
Median fold difference
between day 4 and day 5†
9.6 2.0 7.7 2.0 6.6 2.0 4.1 1.4
*P < .001 for plerixafor versus placebo comparisons in all cell count groups.
†Calculated as the ratio of median absolute PB CD34+ cells/mL on day 5 to that on day 4.
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Figure 2. Proportion of patients collecting the minimum stem cell dose ($2 106 CD341 cells/kg) in 1 day (black), 2 days (black1 dark gray), 3 days
(black1 dark gray1 light gray), and 4 days (black1 dark gray1 light gray1white) of apheresis. Data in the graph are summarized in the table. P values
apply to plerixafor versus placebo comparisons for a given cell count group on a given day of apheresis.
1568 Biol Blood Marrow Transplant 18:1564-1572, 2012A. P. Nademanee et al.apheresis comparedwith those in the placebo group, re-
gardless of cell count group (Table 3). For example,
plerixafor-treated patients in the \20 cells/mL cell
count group collected the minimum cell dose at a me-
dian of 1 day, compared with 2 days in placebo-
treated patients in this cell count group (P \ .001).
Likewise, patients in the plerixafor group collected
the optimum cell dose at a median of 2 days, compared
with 3 days for patients in the placebo group (P\ .001).
Transplantation and engraftment
Across all cell count groups, the proportion of pa-
tients proceeding to HSCT was similar in the plerixa-
for and placebo groups (plerixafor, 97.5%-100%;
placebo, 93.3%-98.6%). The median times to neutro-
phil engraftment (11 days) and platelet engraftment
(18-20 days) after first HSCT were similar in the 2
groups across all cell count groups. A total of 28
plerixafor-treated patients (21.7%) and 26 placebo-
treated patients (20.2%) underwent a second HSCT.DISCUSSION
In this post hoc analyses, stratification of patients by
PB CD341 cell count before apheresis revealed that
116 of the 258 patients (45.0%) had a preapheresis PB
CD341 cell count \20 cells/mL, classifying them aspotential ‘‘slow’’ or ‘‘poor’’ mobilizers. Our findings
demonstrate that compared with placebo plus G-CSF,
the use of plerixafor plusG-CSF significantly improved
the likelihood of successful HSC collection within 4
days in all cell count groups of ‘‘poor’’mobilizers.How-
ever, because the\15 cells/mL and\20 cells/mL cell
count groups analyzed contained a significant number
of patients from the\10 cells/mL group, we are unable
to draw conclusions for patients whose day-4 counts fell
between 10 and 19 cells/mL. Nonetheless, the advanta-
ge of plerixafor plus G-CSF for the poorest of the poor
mobilizers (ie, those in the\10 cells/mL group) is sig-
nificant and remains so evenwhen their numbers are di-
luted by the addition of patients whose day-4 counts fell
into intermediately poor ranges (those between 10 and
19 cells/mL, represented by the\15 and\20 cells/mL
cell count groups). A significantly higher proportion
of the slow mobilizers in the plerixafor group achieved
minimum and optimumHSC collection on all 4 days of
apheresis. Reciprocally, the median time to collection
of the minimum and optimum HSC yields was signifi-
cantly shorter in the plerixafor group (Table 3). These
findings demonstrate that plerixafor can improve
HSC collection and mobilization in poor mobilizers,
beginning as early as day 1 of apheresis.
Our findings also demonstrate that plerixafor plus
G-CSF significantly improves the likelihood of opti-
mum HSC collection in patients with adequate
Figure 3. Proportion of patients collecting the optimum stem cell dose ($6 106 CD341 cells/kg) in 1 day (black), 2 days (black1 dark gray), 3 days
(black1 dark gray1 light gray), and 4 days (black1 dark gray1 light gray1white) of apheresis. Data in the graph are summarized in the table. P values
apply to comparisons of plerixafor-treated and placebo-treated patients for a given cell count group on a given day of apheresis.
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with Low Peripheral Blood CD34+ Cell Countpreapheresis PB CD341 cell counts ($20 cells/mL).
Similar to the results in poor mobilizers, a significantly
higher proportion of patients in the plerixafor group
with a preapheresis CD341 count $20 cells/mL
achieved optimum HSC collection at days 1, 2, 3,
and 4 of apheresis and had significantly higher HSCFigure 4. Median cumulative CD341 cells/kg collected in 1 day (black), 2 day
(black1 dark gray1 light gray1white) of apheresis. P\.001 for plerixafor ver
mL,\20 cells/mL, and $20 cells/mL groups on day 4; P 5 .003 for plerixafor veyields on each apheresis day, resulting in significantly
fewer days of apheresis to achieve optimum HSC col-
lection yields. Collectively, these results indicate that
plerixafor can predictably improve HSC mobilization
and collection in both patients with a low preapheresis
PB CD341 cell count (\20 cells/mL) and those withs (black1 dark gray), 3 days (black1 dark gray1 light gray), and 4 days
sus placebo in all cell count groups on days 1, 2, and 3 and in the\15 cells/
rsus placebo in the\10 cells/mL group on day 4.
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1570 Biol Blood Marrow Transplant 18:1564-1572, 2012A. P. Nademanee et al.a high preapheresis PB CD341 cell count ($20 cells/
mL). Consistent with previous reports, the magnitude
of the increase in PB CD341 cells was at least 3-fold
greater in the plerixafor group compared with the pla-
cebo group across all cell count groups and was more
pronounced in the patients with lower preapheresis
PB CD341 cell counts.
An important finding of this study is thatmore than
80% of the plerixafor-treated patients in each cell
count group collected the minimal transplantable
stem cell dose on the first day of apheresis. Additional
analyses revealed a strong positive correlation between
median stem cell collection on day 1 of apheresis and
median total stem cell collection in both the plerixafor
and placebo groups (plerixafor: r 5 0.90, P\ .0001;
placebo: r 5 0.73, P \ .0001) [16]. The median
CD341 cell count collected on day 1 was higher in
the plerixafor group (7.01  106 cells/kg versus
2.29  106 cells/kg; P\ .001), which translated into
better overall collection in the plerixafor group
(10.96  106 cells/kg versus 6.18  106 cells/kg;
P\ .001). In both the plerixafor and placebo groups,
a negative correlation was found between the median
CD341 cell collection on day 1 and themedian number
of apheresis days needed to collect the minimum
(P\ .001) and optimum (P\ .001) CD341 cell doses.
Consequently, better day-1 collection in the plerixafor-
treated patients resulted in significantly fewer apheresis
days needed to achieve the target collection.
The efficacy of plerixafor in eliciting higher yields
in HSC collection is an important aspect of MM dis-
ease management, given that measures of optimal en-
graftment have been shown to be directly related to
the number of CD341 cells infused [17,18]. Thus,
the ability to collect the optimal stem cell dose
($6  106 CD341 cells/kg) rather than the minimum
dose ($2  106 CD341 cells/kg) likely would have
a significant impact on patient response. In addition,
the ability to collect sufficient HSCs for more than
one transplantation procedure may allow patients to
undergo tandem HSCT, which has been shown to
confer a survival advantage in patients who do not
achieve a very good partial or complete response after
one transplantation [19,20]. In addition, the
collection of sufficient HSCs may allow for a second
transplantation as part of second-line therapy after re-
lapse [21]. Failure rates for current mobilization regi-
mens reported in the literature vary; however, in one
of the largest studies of its kind, Pusic et al. [8] found
that 26.8% of patients who received G-CSF alone col-
lected an optimum cell dose (defined as 5  106 cells/
kg) after 5 days of apheresis. In our analysis, in patients
with a low PBCD341 cell count (\20 cells/mL) treated
with placebo plus G-CSF, the median total yields were
short of optimum (Figure 4), with 36.7% of patients
collecting the optimum cell dose, thereby precluding
tandem HSCT in the majority of these patients. The
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median total stem cell yields in patients with a preaphe-
resis cell count\20 cells/mL and increased their likeli-
hood of achieving the optimum cell dose (62.5%),
making them eligible for tandem HSCT if warranted.
A similar advantage of plerixafor plusG-CSF in achiev-
ing the optimum stem cell dose was demonstrated in
the 3102 Study, which found that treatment with pler-
ixafor plus G-CSF resulted in 37.2% more patients
achieving an optimal CD341 cell count (defined as
6  106 cells/kg) in 2 or fewer apheresis days (71.6%
in the plerixafor plus G-CSF group versus 34.4% in
the placebo plus G-CSF group) [15]. Although no
safety analyses for the specific subsets of patients have
been performed, the cumulative safety data for patients
in the randomized 3102 Study show a similar overall
incidence of adverse events in the plerixafor and pla-
cebo groups. The most common plerixafor-related ad-
verse eventsweremild tomoderate gastrointestinal and
injection site reactions [15].
At this time, the International Myeloma Working
Group acknowledges the potential for plerixafor to
positively affect HSC collection strategies but has not
made recommendations for its standard use in patients
with MM [22,23]. The International Myeloma
Working Group has suggested that health economics
or cost analyses are needed before the routine use of
plerixafor can be recommended [22,23]. Shaughnessy
et al. [24], in a retrospective economic analysis compar-
ing patients mobilized using plerixafor plus G-CSF
with matched historical controls mobilized with cyclo-
phosphamide plus G-CSF, found no significant differ-
ence in mean or median cost of mobilization; the
acquisition cost of plerixafor was offset primarily by
the increased G-CSF use in the cyclophosphamide
plus G-CSF group. Furthermore, no patient in the
plerixafor plus G-CSF group required a weekend
apheresis procedure, compared with 48% of patients
in the control group. That study used Centers for
Medicare and Medicaid reimbursement rates to com-
pare costs, and was not able to adjust for cost differen-
tials that might be associated with weekend apheresis
[24]. Costa et al. [25] have developed an algorithm to
guide plerixafor use based on both PB CD341 cell
counts and an analysis of financial charges and includ-
ing the desired target apheresis yield. In this algorithm,
lower PB CD341 cell counts predicted a financial ad-
vantage with the addition of plerixafor to the mobiliza-
tion regimen on day 4 and beyond [25]. Extending
those findings, our analysis suggests that all patients
with a PBCD341 cell cutoff of\20 cells/mL should re-
ceive plerixafor, because the probability of failing to
achieve theminimal cell dose in 1 or 2 days of apheresis
is 60% and 33%, respectively, with G-CSF alone,
compared with only 18% and 5% with plerixafor
plus G-CSF. As previously noted, collection
of $6  106 CD341 cells/kg has been advocated fortandemHSCT and for secondHSCT at the time of re-
lapse. If the goal is to collect$6 million cells in as few
procedures as required, then adding plerixafor in pa-
tients with higher PB CD341 cell counts ($20 cells/
mL) may be an important therapeutic option, given
that this target was achieved in 86% of patients in the
plerixafor group in 2 days of apheresis, compared
with 55% of those in the placebo group.
Limitations of this study include its retrospective na-
ture and the potential for significant variation in PB
CD341 cell count measurements among laboratories.
In addition, the study did not include G-CSF plus che-
motherapy as a comparative arm;however, this is because
the benefits of adding chemotherapy remain controver-
sial in patients with MM, and currently, there are no
approved chemotherapeutic agents for mobilization.
Taken together, our findings support the use of
up-front plerixafor in patients with MM regardless of
PB CD341 cell count, to increase the number of circu-
lating CD341 cells and improve the likelihood of ob-
taining minimal and optimal HSC yields for ASCT
in just a few days of apheresis. These findings can pro-
vide guidance in developing institutional algorithms
for future stem cell mobilization.ACKNOWLEDGMENTS
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